Dose Response Study in Japanese Patients
NCT00261417
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
250
Enrollment
INDUSTRY
Sponsor class
Stopped
The development program has been terminated
Conditions
Type 2 Diabetes
Interventions
DRUG:
Tesaglitazar
Sponsor
AstraZeneca